Impact of hemostasis parameters on thrombolysis results in acute vascular pathology: 616.13-089

Abstract

Summary. Systemic and selective thrombolysis is one of the commonly used methods for treating patients with acute vascular pathology, such as ischemic stroke, myocardial infarction, acute ischemia of the lower extremities. However, in some cases its use does not lead to the desired results and may be accompanied by life-threatening complications, including major and minor bleeding. To date, in clinical practice there is a lack of clear criteria for determining the clinical and technical effectiveness of thrombolysis, on the one hand, and the risk of hemorrhagic complications, on the other hand. The blood clotting system plays an important role in the development of these complications. Currently, there is an expanding understanding of the role of the primary markers of the blood coagulation system in the pathogenesis of many cardiovascular diseases. Understanding the functioning and interaction between coagulation and fibrinolytic blood systems in acute vascular pathology and thrombolysis can reveal predictors of adverse outcomes, which, in turn, will contribute to improving the effectiveness and safety of this treatment. This article presents a comprehensive overview of various blood clotting factors and markers studied in the context of thrombolysis outcomes in patients with acute vascular pathology. It is concluded that laboratory definition of von Willebrand factor, factors VIII, XIII, VII, thrombin production, and thrombin-antithrombin complex should be expanded for more accurate prediction of thrombolysis outcomes.

For citation: Klimentova E.A., Kalinin R.E., Pshennikov A.S., Egorov A.A., Suchkov I.A. Impact of hemostasis parameters on thrombolysis results in acute vascular pathology. Tromboz, gemostaz i reologiya. 2024;(2):4–12. (In Russ.).

References

1. Zenych A., Fournier L., Chauvierre C. Nanomedicine progress in thrombolytic therapy. Biomaterials. 2020;258:120297. DOI: 10.1016/j.biomaterials.2020.120297.
2. Fluck F., Augustin A. M., Bley T., Kickuth R. Current treatment options in acute limb ischemia. Rofo. 2020;192(4):319–26. DOI: 10.1055/a-0998-4204.
3. Zhou Z., Yoshimura S., Delcourt C. et al. Thrombolysis outcomes in acute ischemic stroke by fluid-attenuated inversion recovery hyperintense arteries. Stroke. 2020;51(7):2240–3. DOI: 10.1161/ STROKEAHA.119.028550.
4. Wu Y., Chen H., Liu X. et al. A new nomogram for individualized prediction of the probability of hemorrhagic transformation after intravenous thrombolysis for ischemic stroke patients. BMC Neurol. 2020;20(1):426. DOI: 10.1186/s12883-020-02002-w.
5. Gram J., Munkvad S., Leebeek F.W. et al. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator. Coron Artery Dis. 1993;4(4):371– 7. DOI: 10.1097/00019501-199304000-00009.
6. Ogiwara K., Nogami K., Nishiya K., Shima M. Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. Blood Coagul Fibrinolysis.2010;21(6):568–76. DOI: 10.1097/MBC.0b013e32833c9a9f.
7. Vorobyeva N.A., Vorobyeva A.I., Kashevarova M.I. et al. Endothelial dysfunction as a marker of thrombotic readiness in the Arctic region. Tromboz, gemostaz i reologiya. 2023;(4):40–48. (In Russ.). DOI: 10.25555/THR.2023.4.1076.
8. Pedersen O.D., Gram J., Jespersen J. Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease. Heart. 1997;77(2):122–7. DOI: 10.1136/hrt.77.2.122.
9. Letunica N., Van Den Helm S., McCafferty C. et al. Proteomics in thrombosis and hemostasis. Thromb Haemost. 2022;122(7):1076– 84. DOI: 10.1055/a-1690-8897.
10. Orbán-Kálmándi R., Szegedi I., Sarkady F. et al. A modified in vitro clot lysis assay predicts outcomes and safety in acute ischemic stroke patients undergoing intravenous thrombolysis. Sci Rep. 2021;11(1):12713. DOI: 10.1038/s41598-021-92041-1.
11. Risman R. A., Kirby N. C., Bannish B. E. et al. Fibrinolysis: an illustrated review. Res Pract Thromb Haemost. 2023;7(2):100081. DOI: 10.1016/j.rpth.2023.100081.
12. Surma S., Banach M. Fibrinogen and atherosclerotic cardiovascular diseases — review of the literature and clinical studies. Int J Mol Sci. 2021;23(1):193. DOI: 10.3390/ijms23010193.
13. Bialkower M., Garnier G. Fibrinogen diagnostics in major hemorrhage. Crit Rev Anal Chem. 2022;52(1):194–209. DOI: 10.1080/1 0408347.2020.1793098.
14. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220(3):251–68. DOI: 10.1097/00000658-199 409000-00003.
15. Ouriel K., Kandarpa K., Schuerr D.M. et al. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol. 1999;10(8):1083– 91. DOI: 10.1016/s1051-0443(99)70196-x.
16. Аrepally A., Hofmann L.V., Kim H.S. et al. Weight-based rt-PA thrombolysis protocolfor acute native arterial and bypass graft occlusions. J Vasc Interv Radiol. 2002;13(1):45–50.DOI: 10.1016/ s1051-0443(07)60008-6.
17. HullJ.E., HullM.K., UrsoJ.A., ParkH.A.Tenecteplase in acute lower-leg ischemia: efficacy, dose, and adverse events. J Vasc Interv Radiol. 2006;17(4):629–36.DOI: 10.1097/01. RVI.0000202751.74625.79.
18. Marder V.J., Comerota A.J., Shlansky-Goldberg R.D. et al. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results. J Thromb Haemost. 2012;10(6):985–91. DOI: 10.1111/j.1538-7836.2012.04728.x.
19. Skeik N., Gits C.C., Ehrenwald E., Cragg A.H. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis. Vasc Endovascular Surg. 2013;47(7):519–23. DOI: 10.1177/1538574413497107.
20. Lee K., Istl A., Dubois L. et al. Fibrinogen level and bleeding risk during catheter-directed thrombolysis using tissue plasminogen activator. Vasc Endovasc Surg. 2015;49(7):175–9. DOI: 10.1177/1538574415611234.
21. Laroia S., Alexander S., Morales S.A. et al. Making the best out of lab values; correlation of fibrinogen level with rate of thrombus resolution during tissues plasminogen (TPA) therapy. J Vasc Interv Radiol. 2015;26(2): S159–S160. DOI: 10.1016/j.jvir.2014.12.429.
22. Raabe R.D. Ultrasound-accelerated thrombolysis in arterial and venous peripheral occlusions: fibrinogen level effects. J Vasc Interv Radiol. 2010;21(8):1165–72. DOI: 10.1016/j.jvir.2010.03.020.
23. Lu T., Xian W., Liang J. et al. Early changes in fibrinogen after administration of alteplase are associated with the short-term efficacy of thrombolysis. Medicine (Baltimore). 2018;97(13):e0241.DOI: 10.1097/MD.0000000000010241.
24. Sun X., Berthiller J., Derex L. et al. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome. J Neurol Sci. 2015;349(1–2):77–83. DOI: 10.1016/j.jns.2014.12.029.
25. Tanne D., Macko R.F., Lin Y. et al.; NINDS rtPA Stroke Study Group. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke. 2006;37(7):1798–804. DOI: 10.1161/01.STR.0000226897.43749.27.
26. Grover S.P., Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25. DOI: 10.1161/ATVBAHA.117.309846.
27. Martí-Fàbregas J., Borrell M., Cocho D. et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology. 2005;65(3):366–70. DOI: 10.1212/01. wnl.0000171704.50395.ba.
28. Byskov K., Etscheid M., Kanse S. M. Cellular effects of factor VII activating protease (FSAP). Thromb Res. 2020;188:74–8. DOI: 10.1016/j.thromres.2020.02.010.
29. Bustamante A., Díaz-Fernández B., Giralt D. et al. Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke. Int J Stroke. 2016;11(6):646–55. DOI: 10.1177/1747493016641949.
30. Lefkovits J., Malycky J.L., Rao J.S. et al. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J Am Coll Cardiol. 1996;28(7):1858–65. DOI: 10.1016/S0735-1097(96)00401-9.
31. Speidel C.M., Thornton J.D., Meng Y.Y. et al. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Artery Dis. 1996;7(1):57–62.
32. Szegedi I., Orbán-Kálmándi R., Nagy A. et al. Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. PLoS One. 2021;16(7):e0254253. DOI: 10.1371/journal.pone.0254253.
33. Kattula S., Bagoly Z., Tóth N.K. et al. The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations. J Thromb Haemost. 2020;18(4):885–94. DOI: 10.1111/ jth.14744.
34. Zhang L., Zhang C., Luo Y. et al. Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis. Ann Palliat Med. 2021;10(7):7579– 86. DOI: 10.21037/apm-21-1174.
35. Székely E.G., Czuriga-Kovács K.R., Bereczky Z. et al. Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients. Sci Rep. 2018;8(1):7662. DOI: 10.1038/ s41598-018-26025-z.
36. Kalinin R.E., Suchkov I.A., Mzhavanadze N.D. et al. Von Willebrand factor in patients with peripheral artery disease who undergo invasive treatment. Rossijskij mediko-biologicheskij vestnik imeni akademika I.P. Pavlova. 2021;29(3):389–96. (In Russ.). DOI: 10.17816/ PAVLOVJ79099.
37. Samuelson Bannow B., Recht M., Négrier C. et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43–50. DOI: 10.1016/j. blre.2019.03.002.
38. Faille D., Labreuche J., Meseguer E. et al. Endothelial markers are associated with thrombolysis resistance in acute stroke patients. Eur J Neurol. 2014;21(4):643–7. DOI: 10.1111/ene.12369.
39. Tóth N.K., Székely E.G., Czuriga-Kovács K.R. et al. Elevated factor VIII and von Willebrand factor levels predict unfavorable outcome in stroke patients treated with intravenous thrombolysis. Front Neurol. 2018;8:721. DOI: 10.3389/fneur.2017.00721.
40. Douglas A., Fitzgerald S., Mereuta O.M. et al. Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes. J Neurointerv Surg. 2020;12(6):557–62.DOI: 10.1136/neurintsurg-2019-015410.
41. Sambola A., García Del Blanco B., Ruiz-Meana M. et al. Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy. Thromb Haemost. 2016;115(6):1129–37. DOI: 10.1160/TH15-12-0985.
42. Denorme F., Langhauser F., Desender L. et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. Blood. 2016;127(19):2337–45. DOI: 10.1182/ blood-2015-08-662650.
43. Shea S. M., Thomas K. A., Rassam R. M.G. et al. Dose-dependent von Willebrand factor inhibition by aptamer BB-031 correlates with thrombolysis in a microfluidic model of arterial occlusion. Pharmaceuticals (Basel). 2022;15(12):1450. DOI: 10.3390/ ph15121450.
44. Gurevitz O., Goldfarb A., Hod H. et al. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vasc Biol. 1998;18(2):200–7. DOI: 10.1161/01. atv.18.2.200.
45. Wilson S.J., Connolly T.M., Peters G. et al. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis. Cardiovasc Res. 2019;115(3):669– 77. DOI: 10.1093/cvr/cvy227.
46. Majumder R. Not so fast, antithrombin! Blood. 2023;141(16):1907– 8. DOI: 10.1182/blood.2023019793.
47. Hudák R., Székely E.G., Kovács K.R. et al. Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis. PLoS One. 2017;12(7):e0180477. DOI: 10.1371/journal.pone.0180477.
48. Jang I.K., Gold H.K., Leinbach R.C. et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 1990;67(6):1552– 61. DOI: 10.1161/01.res.67.6.1552.
49. Scharfstein J.S., Abendschein D.R., Eisenberg P.R. et al. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in myocardial infarction. Am J Cardiol. 1996;78(5):503–10. DOI: 10.1016/ s0002-9149(96)00353-0.
50. Fernandez-Cadenas I., Mendioroz M., Munuera J. et al. Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thromb Haemost. 2009;102(4):759– 64. DOI: 10.1160/TH08-06-0398.
51. Garcia-Avello A., Garcia-Frade L.J., Gandarias C. et al. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res. 1994;73(2):109–15. DOI: 10.1016/0049-3848 (94)90085-x.